<DOC>
	<DOCNO>NCT02584075</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( T2DM ) important risk factor cardio-cerebral vascular disease coronary heart disease . GLP-1 kind incretin secrete L-cell locate Ileum . It act incretin hormone protentiating glucose-stimulated insulin release . Recent study report GLP-1 RA protect vascular endothelial prevent vascular atherosclerosis . Investigators design study investigate exenatide 's effect improvement coronary endothelial function evaluate endothelium dependent diastolic function test vascular endothelial active substance related inflammatory factor .</brief_summary>
	<brief_title>Evaluate Effect Exenatide Treatment Coronary Artery Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Females male , age 20 65 year Newly diagnose type 2 diabetes mellitus BMI &gt; 25kg/m2 . HbA1C &gt; 8 % . Type 1 diabetes mellitus , diabetic ketoacidosis , diabetic hyperosmolar coma . Hepatic insufficiency ( ALT AST &gt; 1.5*ULN ) . Renal insufficiency [ Creatinine clearance rate ( Ccr ) ] &lt; 60ml/min estimate MDRD equation ) . Thyroid disease Use antidiabetic , antihypertension antidyslipidemia drug . Pregnant lactate woman . Severe anemia . Acute myocardial infarction stoke . Other condition investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>